Tomas Pascual

Tomas Pascual

UNVERIFIED PROFILE

Are you Tomas Pascual?   Register this Author

Register author
Tomas Pascual

Tomas Pascual

Publications by authors named "Tomas Pascual"

Are you Tomas Pascual?   Register this Author

18Publications

484Reads

39Profile Views

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.

Oncologist 2019 May 1;24(5):603-611. Epub 2019 Feb 1.

Department of Medical Oncology and Hematology, Hospital Clínico Universitario, University of Valencia-INCLIVA Health Research Institute, CIBERONC, Valencia, Spain.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/lookup/doi/10.1634/th
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2018-0228DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516119PMC
May 2019

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer.

J Immunother Cancer 2019 Mar 29;7(1):90. Epub 2019 Mar 29.

Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0548-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439986PMC
March 2019

Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer.

Cancer Treat Rev 2018 Jun 7;67:63-70. Epub 2018 May 7.

Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain; SOLTI Breast Cancer Cooperative Group, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.04.015DOI Listing
June 2018

Intrinsic molecular subtypes of HER2+ breast cancer.

Oncotarget 2017 Sep 4;8(43):73362-73363. Epub 2017 Sep 4.

Aleix Prat: Department of Medical Oncology, Hospital Clínic de Barcelona, Spain and Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.20629DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650264PMC
September 2017

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.

Breast 2017 Aug 4;34 Suppl 1:S19-S26. Epub 2017 Jul 4.

Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2017.06.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050048PMC
August 2017

Is Metastatic Disease the Best Setting for Cost-Effectiveness Studies?

J Clin Oncol 2016 09 18;34(26):3226-7. Epub 2016 Jul 18.

Hospital del Mar, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2534DOI Listing
September 2016

The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.

Breast 2014 Jun 1;23(3):201-8. Epub 2014 Mar 1.

Medical Oncology Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, 28041 Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2014.01.016DOI Listing
June 2014